Last updated on September 2016

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies


Brief description of study

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.

Clinical Study Identifier: NCT02343120

Contact Investigators or Research Sites near you

Start Over

Eric Hedrick, MD

Austin Health
Heidelberg, Australia
  Connect »

Eric Hedrick, MD

Melbourne Health
Parkville, Australia
6.96miles
  Connect »

Eric Hedrick, MD

Peter MacCallum Cancer Centre, East Melbourne
Parkville, Australia
7.01miles
  Connect »